Sign In  |  Register  |  About Walnut Creek Guide  |  Contact Us

Walnut Creek, CA
September 01, 2020 1:43pm
7-Day Forecast | Traffic

  • Search Hotels in Walnut Creek Guide

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Todos Medical Ltd (OP: TOMDF )

0.0001 UNCHANGED
Last Price Updated: 11:20 AM EDT, Sep 12, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Todos Medical Ltd

< Previous 1 2 Next >
CapitalGainsReport: Today’s OTC Bounce Watchlist (TOMDF, PHIL, RGBP, AIAD)
CapitalGainsReport: Today’s OTC Bounce Watchlist (TOMDF, PHIL, RGBP, AIAD) 
Via News Direct
Exposures COVID-19
Most Active On The OTC Markets In September – A Look Back As October Comes To A Close
The SPDR S&P 500 ETF Trust (NYSEARCA: SPY) declined by 9.62% in September – its largest decline in 2022. 
Via Benzinga
A Quick Look At The OTC Markets' Most-Active Securities In August - Here's What You Need to Know
While July gave markets around the world a breather, August reestablished 2022’s choppy financial conditions. 
Via Benzinga
Todos Medical To Present At The Emerging Growth Conference
- Wednesday, April 27, 2022 at 10:00am – 10:45am EST - 
Via Benzinga
Todos Medical Appoints Philippe Goix As Chief Commercial Officer For Provista Diagnostics
Strengthens Management Team and Positions the Company for Growth and Expansion 
Via Benzinga
Todos Medical Targets Athlete Support with Informed Sport Certification for Tollovid® by LGC Group
New York, NY, and Tel Aviv, ISRAEL – April 19, 2022 - Todos Medical, Ltd. 
Via Benzinga
Meet The Company Developing Advanved Blood Tests To Detect Cancer And Other Diseases
Gerald Commisiong, CEO of Todos Medical Ltd. (OTCQB: TOMDF), was a guest speaker at Benzinga’s All Access on August 5th, 2022. Todos Medical is a leading in vitro diagnostics company developing of... 
Via Benzinga
Todos Medical Receives New FDA Certificate of Free Sale for Tollovid® Max Strength including 5 Day Dosing, 30 Day Dosing And 3CL Protease (3CLpro, Mpro, Nsp5) Inhibitor Claim
5-day and 30-day dosing regimen for 60-pill bottle allows for both support (5-day dosing) to reduce 3CL protease levels and to maintain (30-day dosing) low 3CL protease levels 
Via Benzinga
Todos Medical Initiates IRB-Waived Tollovid® Market Research Study And Announces 50% Price Reduction Until May 30th, 2022
New York, NY, and Tel Aviv, ISRAEL – April 27, 2022 - Todos Medical, Ltd. 
Via Benzinga
Todos Medical Reports 2nd Long COVID Case Study And Launches Website For Physicians And Pediatricians To Indicate Interest In Participating In Tollovid® Long COVID Clinical Study
New York, NY, and Tel Aviv, ISRAEL – April 20, 2022 - Todos Medical, Ltd. 
Via Benzinga
New Study Reportedly Calls Into Question Merck's Ivermectin COVID Off Label Use And May Bolster 3CL Protease Inhibitors Such As Tollovid
Photo credit: Todos Medical This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. 
Via Benzinga
UPDATE: Todos Medical Reports Fourth-Quarter And Full-Year 2021 Financial Results And Corporate Updates
New York, NY, and Tel Aviv, ISRAEL – April 1, 2022 - Todos Medical, Ltd. 
Via Benzinga
Todos Medical Reports Fourth-Quarter And Full-Year 2021 Financial Results And Corporate Updates
New York, NY, and Tel Aviv, ISRAEL – April 1, 2022 - Todos Medical, Ltd. 
Via Benzinga
Todos Medical Reports Case Study Of Patient With Long COVID
New York, NY, and Tel Aviv, ISRAEL, March 31, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. 
Via Benzinga
Billy Blanks® Endorses Todos Medical's Line Of Tollovid® Products
New York, NY, and Tel Aviv, ISRAEL – March 27, 2022 - Todos Medical, Ltd. 
Via Benzinga
Todos Medical Applauds White House Initiative on Long COVID and Announces New Tollovid® US FDA Certificate Of Free Sale With Daily And Acute Dosing On The Label
New York, NY, and Tel Aviv, ISRAEL – April 6, 2022 - Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its majority-owned... 
Via Benzinga
Todos Medical Announces Positive 3CL Protease Inhibition In Vitro Data Against BA.1 and BA.2 Omicron SARS-CoV-2 Variants
New York, NY, and Tel Aviv, ISRAEL – April 4, 2022 - Todos Medical, Ltd. 
Via Benzinga
Todos Medical To Present At The Proactive One2One Virtual Forum
- Thursday, March 17, 2022 at 2:00PM – 2:30PM ET - 
Via Benzinga
Todos Medical Completes Acquisition Of Key Assets And Intellectual Property From NLC Pharma
- Forms new subsidiary, 3CL Pharma, focused on the development and commercialization of 3CL protease-related products including Tollovir™, Tollovid®, Tollovid Daily™ and TolloTest™ for COVID-19 - 
Via Benzinga
Todos Medical To Present At The Emerging Growth Conference
- Wednesday, March 16, 2022 at 1:30 pm – 2 pm EST - 
Via Benzinga
Todos Medical Appoints Greg Meiselbach As Vice President Of Government Affairs
New York, NY, and Tel Aviv, ISRAEL – March 8, 2022 - Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today... 
Via Benzinga
These OTC Securities Reported The Most Trading Volume In January – With Possible Sustained Interest In International Operators
Photo from Jason Briscoe on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. 
Via Benzinga
Benzinga Announces This Week's All Access Guests
Benzinga is thrilled to announce the guest lineup for our next All Access show, sponsored by TiiCKER, set to air Friday, February 11 at 9:15 am ET. The Lineup 9:15 am... 
Via Benzinga
Abbott Labs Outlook Cools the Omicron Led Testing Boom
Photo by Adam Nieścioruk on Unsplash 
Via Benzinga
Todos Medical And NLC Pharma Announce Primary And Secondary Endpoints Met In NLC-V-01 Phase 2 Clinical Trial Of Oral Antiviral 3CL Protease Inhibitor Tollovir™ In The Treatment Of Hospitalized COVID-19 Patients
Phase 2 Study NLC-V-01 closed early after interim data analysis due to positive clinical efficacy 
Via Benzinga
Todos Medical Announces Data Lock in Tollovir™ Phase 2 Clinical Trial for the Treatment of Hospitalized COVID-19 Patients
Clinical Data will be released Thursday, January 27th, 2022 New York, NY, and Tel Aviv, ISRAEL – January 24, 2021 - Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive... 
Via Benzinga
PEPPERDINE UNIVERSITY HOSTS THE 22ND ANNUAL CELEBRITY FLAG FOOTBALL CHALLENGE®, PRESENTED BY TODOS MEDICAL'S TOLLOVID®
In support of First Responders, Military Service Members and Boys and Girls Youth Groups MALIBU, CALIFORNIA January 19, 2022: Working along with the NFL Host Committee, Celebrity... 
Via Benzinga
Todos Medical Releases Videos of Recent CEO Interviews with Fox Business, NewsMax and Black News Channel on COVID Testing & Treatment Strategies
New York, NY, and Tel Aviv, ISRAEL – January 18, 2022 - Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today released... 
Via Benzinga
Todos Medical to Announce Topline Results from Tollovir™ Phase 2 Clinical Trial from the Treatment of Hospitalized COVID-19 Patients on January 27th, 2022
CEO Fox Business Interview discussing COVID testing and solutions to address the crisis now online at https://video.foxbusiness.com/v/6291325085001#sp=show-clips New York... 
Via Benzinga
Todos Medical CEO to Appear on Fox Business to Talk COVID Testing & Tollovir™ on Tuesday, January 11, 2022 and is Presenting at Biotech Showcase 2022
“COVID Testing: What Needs to Happen Now to Turn the Corner in 2022” CEO blog released New York, NY, and Tel Aviv, ISRAEL – January 10, 2022 - Todos Medical,... 
Via Benzinga
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 WalnutCreekGuide.com & California Media Partners, LLC. All rights reserved.